Idioma:

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Ong, Kwok-Leung ; Januszewski, Andrzej S. ; O’Connell, Rachel ; Jenkins, Alicia J. ; Xu, Aimin ; Sullivan, David R. ; Barter, Philip J. ; Hung, Wei-Ting ; Scott, Russell S. ; Taskinen, Marja-Riitta ; Keech, Anthony C. ; Rye, Kerry-Anne

Diabetologia, 2015-03, Vol.58 (3), p.464-473 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por

Enviar para

Título:
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
Autor: Ong, Kwok-Leung ; Januszewski, Andrzej S. ; O’Connell, Rachel ; Jenkins, Alicia J. ; Xu, Aimin ; Sullivan, David R. ; Barter, Philip J. ; Hung, Wei-Ting ; Scott, Russell S. ; Taskinen, Marja-Riitta ; Keech, Anthony C. ; Rye, Kerry-Anne
Assuntos: Aged ; Cardiovascular Diseases - blood ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Enzyme-Linked Immunosorbent Assay ; Female ; Fenofibrate - therapeutic use ; Fibroblast Growth Factors - blood ; Human Physiology ; Humans ; Hypolipidemic Agents - therapeutic use ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Risk Factors ; Stroke - blood
É parte de: Diabetologia, 2015-03, Vol.58 (3), p.464-473
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Descrição: Aims/hypothesis Circulating fibroblast growth factor 21 (FGF21) levels are often elevated in obesity, dyslipidaemia, insulin resistance and type 2 diabetes. This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes. Methods Plasma FGF21 levels were measured by ELISA at baseline in 9,697 individuals with type 2 diabetes participating in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. We assessed the association of FGF21 levels with the incidence of different cardiovascular outcomes over 5 years. The primary outcome was total cardiovascular disease (CVD) events and the secondary outcomes were the four individual components: coronary heart disease events, total stroke, CVD mortality and coronary and carotid revascularisation. The tertiary outcome was hospitalisation for angina pectoris. Results Higher baseline FGF21 levels were associated with higher risks of all cardiovascular outcome events after adjusting for the study treatment allocation (all p < 0.01). The associations remained significant for total CVD events and for coronary and carotid revascularisation after further adjusting for confounding factors, with the HR (95% CI) being 1.28 (1.10, 1.50) and 1.26 (1.01, 1.56), respectively, for the highest tertile compared with the lowest tertile (overall effect p = 0.002 and 0.007, respectively). The addition of FGF21 levels to a model including established CVD risk factors predicting total CVD events led to a non-significant increase in the C-statistic but there was a significant improvement in integrated discrimination and net reclassification. Conclusions/interpretation Higher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes. Trial registration: ISRCTN64783481
Editor: Berlin/Heidelberg: Springer Berlin Heidelberg
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Ong, Kwok-Leung ; Januszewski, Andrzej S. ; O’Connell, Rachel ; Jenkins, Alicia J. ; Xu, Aimin ; Sullivan, David R. ; Barter, Philip J. ; Hung, Wei-Ting ; Scott, Russell S. ; Taskinen, Marja-Riitta ; Keech, Anthony C. ; Rye, Kerry-Anne

Berlin/Heidelberg: Springer Berlin Heidelberg

Buscando em bases de dados remotas. Favor aguardar.